ARTICLE | Product Development
Catalysts beyond cystic fibrosis await Vertex after $8.9B year
Along with its successor to blockbuster Trikafta in CF, the biotech is advancing a diversified pipeline encompassing pain, hematology and kidney disease
February 9, 2023 9:20 PM UTC
Coming off an $8.9 billion year with expectations of modest growth in 2023, Vertex is anticipating key milestones in the coming months that could help it attain a goal of marketing five new drugs in the next five years, allowing it to diversify beyond the cystic fibrosis therapies that have built its business.
On a conference call late Tuesday, President and CEO Reshma Kewalramani said the company’s pipeline spans eight disease areas and consists of candidates that could be best in class, each with multibillion-dollar market potential...